Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Geron Corporation

< Previous 1 2 3 4 Next >
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Host Virtual Investor Event on June 14, 2023
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Present at Upcoming Investor Conferences in April
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Proposed Public Offering of Common Stock
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Conference Call for Top-Line Results from IMerge Phase 3
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.